Full Press Release Details
Pharmaceuticals to Participate in Upcoming Conferences
Genuity Rare Disease Biopharma 1x1 Day on February 7 in New York City
Annual Global Healthcare Conference on February 16 in New York City
VICTORIA, British Columbia--(BUSINESS WIRE)--January 26, 2017--Aurinia
Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that
Michael Martin, Chief Operating Officer, and Celia Economides, Associate
VP of Investor Relations, will participate in the Canaccord Genuity Rare
Disease Biopharma 1x1 Day on February 7th in New York City and the
Leerink Partners 6th Annual Global Healthcare Conference on
February 16th at 11:30am ET. A webcast will be available for
the Leerink Conference and can be accessed via the investor section of
the Aurinia website, www.auriniapharma.com. A replay will also be
archived on the site following the event.
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of lupus nephritis (LN), an inflammation of the kidney caused
by Systemic Lupus Erythematosus (SLE) and represents a serious
progression of SLE. The company is headquartered in Victoria, BC and
focuses its development efforts globally. www.auriniapharma.com.
We Seek Safe Harbor.
Aurinia Pharmaceuticals Inc.
Head of IR & Communications